Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Actinium Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Actinium Pharmaceuticals, Inc.

ATNM

Actinium Pharmaceuticals, Inc.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals develops targeted radiotherapies using alpha-emitting isotopes to treat advanced cancers, including myeloid malignancies, solid tumors, and conditioning for cell and gene therapies. Its clinical-stage pipeline features Actimab-A for AML and MDS, Iomab-ACT for conditioning prior to cellular therapies, and ATNM-400 for prostate cancer. The company integrates radioisotope production, drug manufacturing, and clinical development, leveraging proprietary Ac-225 technology and a broad patent portfolio.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Actinium Pharmaceuticals, Inc.

1
1
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Reports $5.5 Million Net Loss in Q1 2026, Focuses on Clinical Pipeline

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Reports $90,000 Revenue and $33.9 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Reports Q3 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Reports Improved Q2 Loss of $6.9 Million, Focuses on Targeted Radiotherapies

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Reports $15.9 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Reports $38.2 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals Reports $11.6M Net Loss, Reduces Workforce by 20% in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments